Table 1 Characteristics of the study population
From: BIRC5 expression by race, age and clinical factors in breast cancer patients
| Â | CBCS | TCGA | ||||
|---|---|---|---|---|---|---|
Total | BIRC5-Low | BIRC5-High | Total | BIRC5-Low | BIRC5-High | |
(n = 2174) | (n = 1630) | (n = 544) | (n = 1095) | (n = 820) | (n = 274) | |
n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
Age | ||||||
 < 50 years | 1137 (52.3) | 787 (48.3) | 350 (64.3) | 295 (27) | 203 (24.8) | 92 (33.6) |
 ≥ 50 years | 1037 (47.7) | 843 (51.7) | 194 (35.7) | 798 (73) | 616 (75.2) | 182 (66.4) |
 Missing |  |  |  | 2 | 2 |  |
Race | ||||||
 Non-Black | 1061 (48.8) | 860 (52.8) | 201 (36.9) | 816 (81.7) | 647 (86.7) | 169 (66.8) |
 Black | 1113 (51.2) | 770 (47.2) | 343 (63.1) | 183 (18.3) | 99 (13.3) | 84 (33.2) |
 Missing |  |  |  | 96 | 75 | 21 |
ER status | ||||||
 Positive | 1389 (64.2) | 1196 (73.7) | 193 (35.7) | 807 (77.2) | 683 (87.2) | 124 (47.1) |
 Negative | 774 (35.8) | 427 (26.3) | 347 (64.3) | 239 (22.8) | 100 (12.8) | 139 (52.9) |
 Missing | 11 | 7 | 4 | 49 | 38 | 11 |
PR status | ||||||
 Positive | 1159 (53.8) | 1003 (62) | 156 (29) | 347 (33.2) | 607 (77.6) | 91 (34.6) |
 Negative | 996 (46.2) | 614 (38) | 382 (71) | 698 (66.8) | 175 (22.4) | 172 (65.4) |
 Missing | 19 | 13 | 6 | 50 | 39 | 11 |
Her2 status | ||||||
 Positive | 329 (15.2) | 244 (15.1) | 85 (15.8) | 164 (17.9) | 127 (18.5) | 37 (16.1) |
 Negative | 1829 (84.8) | 1375 (84.9) | 454 (84.2) | 752 (82.1) | 559 (81.5) | 193 (83.9) |
 Missing | 16 | 11 | 5 | 179 | 135 | 44 |
PAM50 subtype | ||||||
 LumA | 986 (45.4) | 954 (58.5) | 32 (5.9) | 565 (51.7) | 540 (65.9) | 25 (9.1) |
 LumB | 330 (15.2) | 206 (12.6) | 124 (22.8) | 216 (19.8) | 137 (16.7) | 79 (28.8) |
 HER2 | 195 (9.0) | 130 (8.0) | 65 (11.9) | 82 (7.5) | 55 (6.7) | 27 (9.9) |
 Basal | 583 (26.8) | 263 (16.1) | 320 (58.8) | 190 (17.4) | 50 (6.1) | 140 (51.1) |
 Normal | 80 (3.7) | 77 (4.7) | 3 (0.6) | 40 (3.7) | 37 (4.5) | 3 (1.1) |
Tumor stage | ||||||
 Stage I | 722 (33.6) | 605 (37.6) | 117 (21.8) | 182 (17) | 154 (19.3) | 28 (10.4) |
 Stage II | 1056 (49.2) | 741 (46) | 315 (58.7) | 619 (57.9) | 446 (55.8) | 173 (64.1) |
 Stage III | 299 (13.9) | 214 (13.3) | 85 (15.8) | 249 (23.3) | 186 (23.3) | 63 (23.3) |
 Stage IV | 71 (3.3) | 51 (3.2) | 20 (3.7) | 20 (1.9) | 14 (1.8) | 6 (2.2) |
 Missing | 26 | 19 | 7 | 25 | 21 | 4 |
Tumor size | ||||||
 ≤ 2 cm | 978 (45.6) | 824 (51.2) | 154 (28.7) | NA | NA | NA |
 2–5 cm | 924 (43.1) | 629 (39.1) | 295 (54.9) | NA | NA | NA |
 > 5 cm | 244 (11.4) | 156 (9.7) | 88 (16.4) | NA | NA | NA |
 Missing | 28 | 21 | 7 |  |  |  |
ROR-PT | ||||||
 Low | 532 (24.8) | 527 (32.8) | 5 (0.9) | 237 (22.3) | 236 (29.6) | 1 (0.4) |
 Medium | 1079 (50.3) | 906 (56.3) | 173 (32.2) | 587 (55.1) | 493 (61.9) | 94 (35.1) |
 High | 535 (24.9) | 176 (10.9) | 359 (66.9) | 241 (22.6) | 68 (8.5) | 173 (64.6) |
 Missing | 28 | 21 | 7 | 30 | 24 | 6 |